The story behind an unlikely organ that became one of tissue engineering’s most versatile scaffold sources — and the science now underpinning CholeDerm®
An Unlikely Starting Point
When tissue engineers began searching for a natural extracellular matrix (ECM) source for regenerative scaffolds, most attention went to organs and tissues with obvious appeal — skin, small intestine, urinary bladder. The gallbladder was not an obvious candidate. Yet over nearly two decades, a body of research — much of it led by scientists at India’s Sree Chitra Tirunal Institute for Medical Sciences and Technology (SCTIMST) — has shown that the gallbladder wall is, in fact, an exceptionally well-suited source of biomaterial-grade ECM. That research now forms the scientific foundation of CholeDerm®, Alicorn Medical’s indigenously developed tissue-engineered scaffold.
What Made the Gallbladder Wall Worth Investigating
The gallbladder wall — the cholecyst — has a structural profile that tissue engineers look for in an ideal scaffold source: a thin, membranous, collagen-dense fibromuscular layer with a mucosal surface that lends itself to efficient decellularization. Compared to bulkier organs, it offered a scaffold that could be processed into a biomaterial without extensive mechanical or chemical intervention — a quality that would prove important as the research progressed toward gentler, more matrix-preserving isolation methods.
Laying the Foundation (2006–2007)
The earliest work in this field focused on simply characterizing what a decellularized gallbladder matrix actually was. Foundational studies profiled the macromolecular composition and degradation behavior of cholecyst-derived ECM, establishing which structural proteins survived the decellularization process. Follow-up mechanical testing evaluated the matrix’s biaxial tensile properties, and found it to be a weakly anisotropic but structurally viable biomaterial for tissue engineering purposes. Together, these early studies gave researchers a baseline: the gallbladder-derived matrix was mechanically sound and retained key ECM proteins — a green light to pursue it further as a regenerative scaffold. Springer
Proof of Concept: The 2013 Rabbit Wound Study
The real turning point came with in vivo validation. A 2013 study tested a porcine cholecyst-derived scaffold in a rabbit full-thickness wound model — the standard benchmark for evaluating whether a scaffold can genuinely support skin regeneration rather than simply covering a wound. The rationale behind the work was direct: a scaffold that mimics the extracellular matrix with adequate bioactive molecules, capable of supporting the growth of cells involved in regeneration, is an ideal graft for wound healing, and gallbladder-derived matrix — naturally rich in collagen, elastin, glycosaminoglycans, laminin, and fibronectin — fit that description. The study’s results supported the scaffold’s ability to promote full-thickness wound healing, giving the research program its first strong evidence of clinical relevance. DOI
Refining the Biomaterial: Gentler Processing, Safety Validation (2014–2015)
With proof of concept established, research attention turned to how the scaffold was made. Conventional decellularization relies heavily on detergents and enzymes — effective at removing cells, but also capable of stripping away the biomolecules that make ECM scaffolds biologically active in the first place. A 2014 study introduced a non-detergent, non-enzymatic recovery method for isolating cholecyst-derived ECM, using a stabilizing pre-treatment step designed to preserve more of the matrix’s native composition. This gentler-processing principle would later become central to how CholeDerm® itself is manufactured.
Alongside this, researchers began systematically testing the scaffold’s safety profile — comparing its local immunogenicity against ECM scaffolds derived from other tissues, and characterizing its biocompatibility and immune response in animal models. This safety validation work was essential groundwork before the scaffold could be considered for further translational development.
Expanding the Evidence Base: Larger Animal Models (2018)
Rodent and rabbit studies are useful early indicators, but translational credibility requires evidence in more clinically representative settings. A 2018 study tested a porcine cholecyst-derived scaffold on full-thickness lacerated skin wounds in dogs — a larger-animal model closer in scale and healing physiology to human patients — extending the evidence base beyond small-animal proof of concept.
Engineering the Matrix Further (2019–2020)
As the underlying biology became better understood, research shifted toward engineering the scaffold’s physical properties for specific clinical needs. Controlled crosslinking studies explored how to tune the matrix’s degradation rate and mechanical durability without compromising its biological activity. Separately, researchers developed hybrid hydrogel formulations of the same cholecyst-derived matrix, opening the door to injectable applications and use in tissue types beyond skin, including skeletal muscle — a sign that the platform’s usefulness extended well past its original wound-care application.
Functionalizing for Complex Indications (2021–2022)
The most recent phase of this research has focused on adapting the scaffold for harder-to-treat clinical problems. In 2021, researchers chemically coupled gelatin to the cholecyst-derived scaffold specifically to enhance angiogenesis — addressing the compromised blood vessel formation that makes diabetic wounds so difficult to heal, and demonstrating faster healing in a diabetic wound model as a result. In parallel, work on a conductive cholecyst-derived scaffold explored its potential in cardiac tissue repair — a striking illustration of how far the platform had evolved from its original description as a simple wound covering.
From Research Platform to Indian-Made Clinical Product
Nearly two decades of this research — spanning mechanical characterization, safety validation, wound healing efficacy, and functional modification — established the gallbladder-derived ECM scaffold as a well-characterized, versatile regenerative biomaterial platform, developed and validated substantially within Indian research institutions. CholeDerm®, manufactured by Alicorn Medical Private Limited in collaboration with SCTIMST and produced through the enzyme-free, detergent-free PrisTINE Process, is the clinical translation of this research lineage — a CDSCO-approved (Class D), India-made scaffold built on a scientific foundation refined study by study, from 2006 to the present.
Conclusion
The gallbladder was never an obvious choice for tissue engineers — but its dense, collagen-rich, low-cellularity wall turned out to be exactly what a scaffold source needed to be: mechanically sound, biologically preserved through gentle processing, and adaptable across an expanding range of clinical indications. That research trajectory is what stands behind CholeDerm® today.